As home to the first FDA-approved cell and gene therapies, Penn Medicine  and Children’s Hospital of Philadelphia are international leaders who have helped propel Philadelphia into Cellicon Valley, with the  University of Pennsylvania  ranking 1st among global universities for CAR-T cell patents according to Nature.  CAR T represents a turning point in the history of human medicine, a genuine revolution in our approach to disease within the field of cellular therapy and transplant. The approvals of chimeric antigen receptor (CAR) T cells offers even patients with highly chemo-refractory hematologic malignancies additional treatment options. World experts in CAR T-cellular therapy, hematologic malignancies, and hematopoietic stem cell transplantation (HSCT) have been assembled to discuss the development and implementation of this therapy and to weigh in on current applications, best practices, novel strategies and future developments for CAR T cells.

TARGETED AUDIENCE

These activities are intended for both adult and pediatric hematologist-oncologists, medical oncologists, hematologists, hematopathologists, immunologists, immunobiologists, transfusion medicine, researchers, pharmacists, fellows, nurses, nurse practitioners, physician assistants, industry professionals and other healthcare professionals interested in the latest advances in cell and gene therapy. Additionally, patients and their caregivers, family members, advocates and members of the public who may benefit from understanding current innovative approaches to gene and cell therapy are also invited.

EDUCATIONAL OBJECTIVES

Upon completion of this symposium, participants should be able to:

• Identify current application of CAR T-cell therapy including: disease indication, accurate patient selection, manufacturing and treatment administration
• List factors in overcoming resistance to monotherapy CAR’s
• Implement guidelines for patient management of toxicities of CAR T-cell therapies including cytokine release syndrome and neurologic toxicity
• Describe gene delivery and editing for more effective T cell therapies
• Identify the latest targets and technologies for CARs
• Identify the current status of globalization of CAR T-cell therapies and identify principles in ethics of patient access
• Describe current approaches in treatment and supportive care for hematopoietic stem cell transplantation (HSCT) in pediatric patients with nonmalignant conditions
• Identify the latest evidence based standards in nursing care resulting from the recent advances in cell therapy and transplant

For more information please visit the official event page.